WuXi Going Public Again In Selected China, Hong Kong Listings
Executive Summary
China’s WuXi AppTec is planning separate new stock listings for various parts of its business in both China and Hong Kong, potentially raising billions of dollars in the wake of an earlier go-private transaction.
You may also be interested in...
WuXi Biologics Readies For Hong Kong IPO
As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.
WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO
WuXi AppTec is planning to spin out its biologics CRO/CMO unit in a Hong Kong IPO that is likely to raise at least $367m, sources have confirmed. The new funding would provide the fast-growing Wuxi Biologics subsidiary with the freedom and resources to make its own pipeline portfolio decisions.
China Resources Eyes $1bn Hong Kong IPO As It Streamlines Ops
The Chinese state-owned manufacturer and distributor China Resources Pharmaceutical Group is planning an up to $1bn IPO in Hong Kong this year, as part of an ongoing restructuring of its large diversified business and integration of assets.